Quick Answer
Artiva Biotherapeutics, Inc. reported Cash and Equivalents of $26.70 million for fiscal year 2025.
Artiva Biotherapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $26.70M | -33.6% |
| 2024 | $40.23M | -24.8% |
| 2023 | $53.50M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $25.51M | -54.4% | -10.4% |
| June 30, 2025 | $28.47M | -16.9% | -6.4% |
| March 31, 2025 | $30.40M | -36.9% | -24.4% |
| December 31, 2024 | $40.23M | -24.8% | -28.0% |
| September 30, 2024 | $55.88M | -15.2% | +63.2% |
| June 30, 2024 | $34.25M | -36.2% | -28.9% |
| March 31, 2024 | $48.20M | — | -9.9% |
| December 31, 2023 | $53.50M | — | -18.8% |
- Artiva Biotherapeutics, Inc. showed a decrease of -33.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2023–2025 period, Artiva Biotherapeutics, Inc.’s cash and equivalents has declined by 50.1% (from $53.50 million to $26.70 million).
- The most recent figure is from Artiva Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: